Table 1 Regional target product profiles
Target profile | South Asia | Africa |
|---|---|---|
Risk:Benefit | Must be very high Parasitological cure must be achieved | No direct associated mortality with symptomatic treatment |
Ease of use | Feasible to use at the level of a health clinic | |
Course of treatment | Very short course of treatment to facilitate compliance | Minimum acceptable treatment for children: one week (similar to antibiotics) |
Cold chain requirements | Ideally not cold chain dependent | |
Cost factors | Cost is less important than commitment to treatment | |
Concomitant infections | With HIV co-infection, no antimonials or monotherapies |